Ras biochemistry and farnesyl transferase inhibitors: a literature survey von Crul, M, de Klerk, G J, Beijnen, J H, Schellens, J HM

Volltext

Pharmaceutical development of anticancer agents derived from marine sources von Nuijen, B, Bouma, M, Manada, C, Jimeno, J M, Schellens, J HM, Bult, A, Beijnen, J H

Volltext

Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer von Schellens, J HM, Planting, A STh, Ma, J, Maliepaard, M, de Vos, A, de Boer Dennert, M, Verweij, J

Volltext

Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9 von Schellens, J HM, Dombernowsky, P, Cassidy, J, Epelbaum, R, Dirix, L, Cox, E H, Wanders, J, Calabresi, F, Paridaens, R, Monfardini, S, Wolff, J, Loos, W J, Verweij, J, Pavlidis, N, Hanauske, A-R

Volltext

Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands von Kruijtzer, C MF, Verweij, J, Schellens, J HM, Beijnen, J H, Pronk, L, Bo, M, Lustig, V, van Tinteren, H, Mackay, M, Ten Bokkel Huinink, W W

Volltext

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies von Keizer, Ron J., Huitema, Alwin D. R., Schellens, Jan H. M., Beijnen, Jos H.

Volltext

Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer von Geenen, Jill J J, Schellens, Jan H M

Volltext

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers von Fong, Peter C, Boss, David S, Yap, Timothy A, Tutt, Andrew, Wu, Peijun, Mergui-Roelvink, Marja, Mortimer, Peter, Swaisland, Helen, Lau, Alan, O'Connor, Mark J, Ashworth, Alan, Carmichael, James, Kaye, Stan B, Schellens, Jan H.M, de Bono, Johann S

Volltext

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer von Kopetz, Scott, Grothey, Axel, Yaeger, Rona, Van Cutsem, Eric, Desai, Jayesh, Yoshino, Takayuki, Wasan, Harpreet, Ciardiello, Fortunato, Loupakis, Fotios, Hong, Yong Sang, Steeghs, Neeltje, Guren, Tormod K, Arkenau, Hendrik-Tobias, Garcia-Alfonso, Pilar, Pfeiffer, Per, Orlov, Sergey, Lonardi, Sara, Elez, Elena, Kim, Tae-Won, Schellens, Jan H.M, Guo, Christina, Krishnan, Asha, Dekervel, Jeroen, Morris, Van, Calvo Ferrandiz, Aitana, Tarpgaard, L.S, Braun, Michael, Gollerkeri, Ashwin, Keir, Christopher, Maharry, Kati, Pickard, Michael, Christy-Bittel, Janna, Anderson, Lisa, Sandor, Victor, Tabernero, Josep

Volltext

Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time von Lunenburg, Carin A.T.C, Henricks, Linda M, Guchelaar, Henk-Jan, Swen, Jesse J, Deenen, Maarten J, Schellens, Jan H.M, Gelderblom, Hans

Volltext

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours von de Jonge, Maja, de Weger, Vincent A, Dickson, Mark A, Langenberg, Marlies, Le Cesne, Axel, Wagner, Andrew J, Hsu, Karl, Zheng, Wei, Macé, Sandrine, Tuffal, Gilles, Thomas, Koruth, Schellens, Jan H.M

Volltext

Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM von Keizer, Ron J, van Benten, Michel, Beijnen, Jos H, Schellens, Jan H.M, Huitema, Alwin D.R

Volltext

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer von DEENEN, Maarten J, TOL, Jolien, SCHELLENS, Jan H. M, CATS, Annemieke, BURYLO, Artur M, DOODEMAN, Valerie D, DE BOER, Anthonius, VINCENT, Andrew, GUCHELAAR, Henk-Jan, SMITS, Paul H. M, BEIJNEN, Jos H, PUNT, Cornelis J. A

Volltext

P‐glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel von Hendrikx, Jeroen J.M.A., Lagas, Jurjen S., Rosing, Hilde, Schellens, Jan H.M., Beijnen, Jos H., Schinkel, Alfred H.

Volltext

Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the DPYD2A variant: A matched pair analysis von Henricks, Linda M., Merendonk, Lisanne N., Meulendijks, Didier, Deenen, Maarten J., Beijnen, Jos H., Boer, Anthonius, Cats, Annemieke, Schellens, Jan H.M.

Volltext

Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regim... von Meulendijks, Didier, van Hasselt, J.G. Coen, Huitema, Alwin D.R, van Tinteren, Harm, Deenen, Maarten J, Beijnen, Jos H, Cats, Annemieke, Schellens, Jan H.M

Volltext

Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs von Breedveld, Pauline, Beijnen, Jos H., Schellens, Jan H.M.

Volltext

Systematic review of biomarkers to monitor therapeutic response in leishmaniasis von Kip, Anke E, Balasegaram, Manica, Beijnen, Jos H, Schellens, Jan H M, de Vries, Peter J, Dorlo, Thomas P C

Volltext

Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score von Henricks, Linda M, Lunenburg, Carin A T C, Meulendijks, Didier, Gelderblom, Hans, Cats, Annemieke, Swen, Jesse J, Schellens, Jan H M, Guchelaar, Henk-Jan

Volltext

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib von Oostendorp, Roos L., Buckle, Tessa, Beijnen, Jos H., van Tellingen, Olaf, Schellens, Jan H. M.

Volltext